Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770389 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of Obicetrapib in Combination With Ezetimibe
A Phase 2 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT04770389: Completed Phase 2 study, sponsored by NewAmsterdam Pharma.
NCT04770389 is a Phase 2 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 112 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04770389, a Phase 2 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
Primary Outcome
Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula
Interventions
- OTHER Placebo
- DRUG Ezetimibe 10mg
- DRUG Obicetrapib 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
What the finished NCT04770389 record still lists
NCT04770389 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04770389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04770389 about?
NCT04770389 is a clinical study titled "Randomized Study of Obicetrapib in Combination With Ezetimibe". This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
What is the current status of trial NCT04770389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2021-02-23. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04770389?
The interventions under investigation include: Placebo (OTHER), Ezetimibe 10mg (DRUG), Obicetrapib 5mg (DRUG).
Who is sponsoring clinical trial NCT04770389?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04770389's enrollment target sits among peer trials
112 631st of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI